Autolus Therapeutics AUTL

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.06 (-2.90%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Autolus Therapeutics (AUTL)
    Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.01

    • Market Cap

      $534.90 Million

    • Price-Earnings Ratio

      -1.65

    • Total Outstanding Shares

      266.12 Million Shares

    • Total Employees

      463

    • Dividend

      No dividend

    • IPO Date

      June 22, 2018

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      American Depository Receipt Common

    • Headquarters

      The mediaworks, London, X0, W12 7FP

    • Homepage

      https://www.autolus.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-193.17 Million
    Exchange Gains/Losses$47.73 Million
    Net Cash Flow From Financing Activities, Continuing$559.57 Million
    Net Cash Flow From Financing Activities$559.57 Million
    Net Cash Flow From Investing Activities, Continuing$-12.44 Million
    Net Cash Flow$401.69 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Income/Loss From Continuing Operations After Tax$-270.23 Million
    Research and Development$145.15 Million
    Income/Loss From Continuing Operations Before Tax$-270.19 Million
    Income Tax Expense/Benefit$42,000
    Preferred Stock Dividends And Other Adjustments$0
    Net Income/Loss Attributable To Parent$-270.23 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-237.33 Million
    Other Comprehensive Income/Loss$-237.33 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-237.33 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Equity$476.96 Million
    Noncurrent Liabilities$298.05 Million
    Other Non-current Assets$65.12 Million
    Accounts Payable$1.42 Million
    Prepaid Expenses$14.06 Million
    Other Current Liabilities$35.61 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AUTL from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.